Imaging Studies of Cognitive Impairment in Parkinson s Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )
ClinicalTrials.gov Identifier:
NCT01862744
First received: May 23, 2013
Last updated: March 26, 2014
Last verified: February 2014

May 23, 2013
March 26, 2014
April 2013
January 2015   (final data collection date for primary outcome measure)
  • Functional connectivity of cognitive networks using resting-state fMRI between patients with PD-CogNL, PD-MCI or PDD, and HVs. [ Time Frame: ongoing ] [ Designated as safety issue: No ]
  • Correlate MMSE score with functional connectivity of the default mode network in PD patients. [ Time Frame: ongoing ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01862744 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Imaging Studies of Cognitive Impairment in Parkinson s Disease
Neural Correlates of Cognitive Impairment in Parkinson Disease

Background:

- Parkinson's disease causes slow movements, stiffness, and tremor. It can get worse over time, and in some cases can lead to dementia. Researchers are interested in how dementia affects the brain in people with Parkinson's disease. They will study both people with Parkinson s disease and healthy volunteers. They will give tests of thinking and memory, and look at brain activity using imaging studies. This may provide more information on what parts of the brain are not working well in people who have dementia related to Parkinson's disease.

Objectives:

- To use imaging studies to see what parts of the brain do not work well in people with dementia caused by Parkinson's disease.

Eligibility:

  • Individuals at least 40 years of age who have Parkinson s disease.
  • Healthy volunteers at least 40 years of age.

Design:

  • Participants will be screened with a medical history and physical exam.
  • This study requires two outpatient visits over 2 days.
  • Participants will have tests of thinking, memory, and concentration. They will answer questions and fill out questionnaires. The tests will also look at how quickly they can move and handle small objects. The tests will take about 3 hours.
  • Participants will have magnetic resonance imaging to study the brain. Functional MRI (fMRI) can show what parts of the brain are used when performing a task. Participants will respond to images on a computer screen during fMRI.
  • Treatment will not be provided as part of this study.

Objectives:

The purpose of this protocol is to identify the neural correlates of cognitive impairment in

Parkinson disease (PD) using magnetic resonance imaging (MRI).

Study Population:

We will study 36 PD patients, defined by the UK Parkinson s Society Brain Bank diagnostic

criteria [1], consisting of 12 patients with cognitively normal PD (PD-CogNL), 12 with PD

with mild cognitive impairment (PD-MCI) [2], and 12 with PD with dementia (PDD) [3]. We

will also study 12 age- and gender-matched healthy volunteers (HVs) as controls.

Design:

This is an observational study and includes 3 PD patient subgroups (PD-CogNL, PD-MCI and PDD) and HVs group. Eligible participants will have one visit lasting 2- 4 days, ideally over 2 consecutive days. If the visit cannot be completed within that time frame, a second visit may be scheduled within 3 months to complete the assessments. They will have a clinical assessment, cognitive assessment, and MRI scans.

Outcome Measures and Hypothesis:

The primary outcome measure is the Mini-Mental State Examination (MMSE) score and

functional connectivity of cognitive networks, including default mode network, using restingstate

functional MRI (fMRI). We hypothesize that there is a group difference in functional

connectivity of cognitive networks between the PD patient subgroups and HVs. We also

hypothesize that there is a correlation between the MMSE score and functional connectivity

of the default mode network in PD patients.

Secondary outcome measures are fractional anisotropy (FA) values, functional

connectivity of the cognitive networks during working memory tasks, olfactory function

score and the functional connectivity of olfactory network, and scales of brain perfusion and

the functional connectivity of default mode network. We hypothesize that there: 1) is a group

difference in FA values between PD patient subgroups and the HVs; 2) are group differences

in functional connectivity of the cognitive networks during the working memory task

between PD patient subgroups and HVs; 3) is a correlation between olfactory function and

functional connectivity of the olfactory network in patients with PD-CogNL or PD-MCI; and

4) are correlations between brain perfusion and the functional connectivity of the default

mode network in PD patients.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Parkinson Disease
  • Dementia
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
96
January 2015
January 2015   (final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:

For all subjects:

  1. Age 40 or older.
  2. Able to abstain from caffeine and alcohol for 24 hours before each visit.
  3. English is the first language.
  4. Right handed

For PD cohort:

  1. Established diagnosis of PD.
  2. History compatible with diagnosis of PD
  3. Present with at least 3 of the following features: bradykinesia, resting tremor, cogwheel rigidity or postural reflex impairment
  4. One of the 3 clinical features is either bradykinesia or resting tremor
  5. Currently taking or history of taking dopaminergic therapy with symptomatic response.
  6. Is able to give informed consent or, if there is evidence of cognitive decline, able to give assent and able to appoint a durable power of attorney (DPA) who can give informed consent.

EXCLUSION CRITERIA for all subjects:

  • Use of illegal drugs within the past 6 months.
  • More than 7 alcoholic drinks a week for females or 14 alcoholic drinks a week for males.
  • History of a neurologic disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, a movement disorder, epilepsy or a history of seizures, except PD for PD patients.
  • History of any head injury with loss of consciousness.
  • Pregnancy or positive pregnancy test before the research procedure due to the risks associated with MRI scans.
  • Inability to lie flat on the back for up to 2 hours.
  • Claustrophobia or a feeling of discomfort from being in small, enclosed spaces of enough severity to prevent MRI scanning.
  • Surgically or traumatically implanted metallic foreign bodies, such as pacemakers, implanted medical pumps, implanted hearing aids, metal plates in the skull or metal implants in the skull or eyes (other than dental fillings) that may be physically hazardous during an MRI, or might distort the images.
  • Ablative surgery or implanted electrodes and generator for deep brain stimulation
  • Use of the following medications or substances within 6 months of getting MRI scan: e.g., Cocaine, amphetamines, methylphenidate, ephedrine, phentermine, buproprion, fentanyl, ketamine, and phencyclidine. Prescribed medication for common conditions, such as allergy or cold, will not be exclusionary. Prescribed medication for PD will not be exclusionary for PD patient.
  • Have uncontrolled head movements that may impair image data collection (for PD patients).
  • Subjects with MMSE< 26 for HVs.
  • Have clinically relevant focal neurological findings on exam that suggest cerebral pathology other than that associated with PD for PD patients.
  • Any abnormal or focal finding on neurological exam for HVs.
  • Abnormal findings in clinical MRI.
  • PD patients with Beck Depression Inventory (BDI)-II > 31 will be excluded, because severe or extreme depression may confound with cognitive function.
Both
40 Years and older
Yes
Contact: Beverly A McElroy, R.N. (301) 402-4479 mcelroyb@ninds.nih.gov
Contact: Codrin I Lungu, M.D. (301) 402-0976 lunguci@ninds.nih.gov
United States
 
NCT01862744
130115, 13-N-0115
Not Provided
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )
National Institute of Neurological Disorders and Stroke (NINDS)
Not Provided
Principal Investigator: Codrin I Lungu, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC)
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP